Parent D, Decroix J, Heenen M
Department of Dermatology, Erasme Hospital, Free University of Brussels, Belgium.
Dermatology. 1994;189(4):378-81. doi: 10.1159/000246883.
Superficial fungal infections have usually been considered to be caused only by dermatophytes. In recent years their epidemiology has been changing with other fungi being isolated and, thus, antifungal agents with a broad spectrum of activity, such as itraconazole, may be particularly useful. The risk/benefit ratio for any such treatment is determined by its tolerability profile and the duration of therapy.
The aim was to compare the efficacy and tolerance of a shorter treatment regimen, using a higher dose of itraconazole, with a standard itraconazole regimen in the treatment of tinea corporis/cruris.
An open study compared oral itraconazole 200 mg daily for 7 days with oral itraconazole 100 mg for 15 days in 153 patients with tinea corporis/cruris.
At follow-up all patients in both groups were clinically cured or markedly improved. However, mycological cures were greater in the 7-day treatment group (90%), and the onset of clinical and mycological cure was faster in this group.
Itraconazole, 200 mg daily for 7 days, offers a short convenient and effective treatment option for tinea corporis and tinea cruris.
浅表真菌感染通常被认为仅由皮肤癣菌引起。近年来，随着其他真菌的分离，其流行病学发生了变化，因此，具有广泛活性的抗真菌药物，如伊曲康唑，可能特别有用。任何此类治疗的风险/效益比取决于其耐受性和治疗持续时间。
比较高剂量伊曲康唑短疗程治疗方案与标准伊曲康唑方案治疗体股癣的疗效和耐受性。
一项开放性研究比较了153例体股癣患者每日口服200mg伊曲康唑共7天与口服100mg伊曲康唑共15天的疗效。
随访时两组所有患者临床均治愈或明显改善。然而，7天治疗组的真菌学治愈率更高（90%），且该组临床和真菌学治愈的起效更快。
每日200mg伊曲康唑共7天为体股癣提供了一种简短、方便且有效的治疗选择。
